// App-Quantinova.ai

PB0719 : The novel bispecific antibody HMB-001 enhances the haemostatic response in models of Glanzmann Thrombasthenia by targeting FVIIa to activated platelets

Researchers

Presenter

  • M. Zivkovic

Principal Investigators

  • P. Gandhi

  • H. Ostergaard

  • E. Olsen

  • C. Rea

  • J. Faber

  • R. Schutgens

  • R. Urbanus

Medical Centers

  • Hemab Therapeutics, Copenhagen, Hovedstaden, Denmark

  • Hemab Therapeutics, London, England, United Kingdom

  • Akebia Therapeutics Inc Cambridge Massachusetts United States

  • Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, the Netherlands, Utrecht, Utrecht, Netherlands

Locations

  • Netherlands

  • Denmark

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Blood/haematological Diseases

Disease

  • Glanzmann thrombasthenia

Biomarkers

  • Activated factor VII

Drug/Treatment

  • Evithrom

  • rFVIIa

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved